Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

zyme produced at the 2000L capacity and the timing thereof; its plans to seek regulatory approvals of existing products for use in new indications, including Renvela for CKD, the timetables therefore and the impact of such approvals on the company; its plans and estimated timetables for new and next- generation product filings, regulatory actions and launches, including for Mozobil, Clolar, alemtuzumab-MS, mipomersen, Genz-112638 and Synvisc-ONE and the assessment of the market potential of such products; its projected Myozyme revenues for 2008; and its anticipated growth drivers for certain products and businesses, including Genetics and Thymoglobulin. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to successfully complete preclinical and clinical development of its products and product candidates, including Mozobil, Clolar, alemtuzumab-MS, mipomersen, and Genz-112638; Genzyme's ability to expand the use of current and next-generation products in existing and new indications, including Renvela and Synvisc-ONE; Genzyme's ability to obtain and maintain regulatory approvals for products and manufacturing facilities, including Myozyme produced at the 2000L scale in the US and at the 4000L scale in Europe and the timing of receipt of such approvals; Genzyme's ability to manufacture its products, including Thymoglobulin and its LSD therapies in a timely and cost effective manner and in sufficient quantities to meet demand; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2007 Annual Report on Form 10-K. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date
'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Hussey Copper , a ... antimicrobial copper announces Pullman Regional Hospital,s conversion of ... antimicrobial solid touch surface, at a nominal cost.  This ... E-coli and other bacteria within 2 hours of exposure 1 ... bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... 22, 2014  United Therapeutics Corporation (NASDAQ: ... release its second quarter 2014 financial results before ... United Therapeutics will host a half-hour teleconference ... Eastern Time.  The teleconference is accessible by dialing ... of the teleconference will be available for one ...
(Date:7/22/2014)... 2014 Dr. Williams says, “Bush has ... recognized that the greatest health care system in the ... needlessly deadly while trying to serve the public. Unfortunately, ... to transform an enormous system that none of them ... his continuing series of Open Letters ( http://is.gd/wdU2CM ) ...
(Date:7/21/2014)... yield so far is small, but chemists at the ... substitution process to make a precursor to transparent thin ... energy devices. , A paper describing the approach is ... of the journal Inorganic Chemistry , which draws ... nuclear chemistry fields. The paper was chosen by the ...
Breaking Biology Technology:Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Oregon chemists eye improved thin films with metal substitution 2
... , ... goBalto.com introduces a new project management tool - "Projects" - to help ... management tools can be awkward and cumbersome. goBalto Projects takes on project management ... time and money. , ...
... , PHOENIX and SAN CARLOS, Calif., Oct. 10 ... data today from its Phase 2 clinical trial of ... (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona. ... stage investigational product candidate in clinical development for the ...
... of Toronto have developed a new "lab-on-a-chip" technique that analyses ... at risk of breast cancer much more quickly than ever ... metabolites the products of metabolized estrogen in breast ... patients compared to healthy women, and is therefore believed to ...
Cached Biology Technology:goBalto Introduces Web-based Solution to Manage Drug-development Collaborations 2Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 2Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 3Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 4New lab-on-a-chip technique developed at U of T 2
(Date:7/22/2014)... of planthopper known as Conosimus, which now includes six ... the southern part of the Iberian Peninsula in the ... in the open-access Journal of Insect Science ... Conosimus baenai , has been named after Manuel Baena, ... of Iberian Hemiptera. , Conosimus baenai differs ...
(Date:7/21/2014)... a professor of entomology and cooperating faculty ... the University of California, Riverside, has been awarded the ... of Chemical Ecology ( ISCE ). , Awarded first ... the society,s highest honor. It is awarded annually to ... the study of chemicals that mediate interactions between living ...
(Date:7/21/2014)... to monitor seals, every movement, researchers have shown for ... to offshore wind farms and pipelines. Those man-made structures ... according to a study published in the Cell Press ... , "I was shocked when I first saw the ... Shoal," an offshore wind farm in the United Kingdom, ...
Breaking Biology News(10 mins):UC Riverside entomologist receives international honor for chemical ecology contributions 2Seals forage at offshore wind farms 2
... the egg genome? Researchers have answered a similarly vexing ... of long stretches of repeated DNA in the human genome ... published online by Nature Genetics on October 7, ... the human genome that are partly responsible for both disease ...
... CITY, Utah - Mario R. Capecchi, Ph.D., distinguished professor ... Utahs Eccles Institute of Human Genetics and a Howard ... Prize in Physiology or Medicine. The announcement was ... Karolinska Institute, in Stockholm, Sweden. The prize recognizes Capecchis ...
... of Cincinnati (UC) radiologists have developed a new ... eases diagnosis of venous diseases. Multi-detector computed ... three-dimensional images of arteries, the vessels which carry ... blood throughout the body. Veins, smaller vessels that ...
Cached Biology News:Which came first, the chicken genome or the egg genome? 2Which came first, the chicken genome or the egg genome? 3Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 2Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 3New thoracic imaging approach can pinpoint underlying venous problems 2
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
Biology Products: